Q1 2025 13F Holders as of 31 Mar 2025
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
80,797,753
-
Number of holders
-
171
-
Total 13F shares, excl. options
-
72,808,716
-
Shares change
-
+1,093,234
-
Total reported value, excl. options
-
$1,995,263,098
-
Value change
-
+$5,348,226
-
Put/Call ratio
-
108%
-
Number of buys
-
84
-
Number of sells
-
-85
-
Price
-
$27.37
Significant Holders of Kymera Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KYMR) as of Q1 2025
212 filings reported holding KYMR - Kymera Therapeutics, Inc. - Common Stock, $0.0001 par value per share as of Q1 2025.
Kymera Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KYMR) has 171 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 72,808,716 shares
of 80,797,753 outstanding shares and own 90% of the company stock.
Largest 10 shareholders include PRICE T ROWE ASSOCIATES INC /MD/ (6,702,450 shares), Avoro Capital Advisors LLC (6,460,000 shares), WELLINGTON MANAGEMENT GROUP LLP (5,996,873 shares), BAKER BROS. ADVISORS LP (5,995,929 shares), VANGUARD GROUP INC (5,231,392 shares), BVF INC/IL (5,161,801 shares), Atlas Venture Life Science Advisors, LLC (4,896,462 shares), FMR LLC (4,409,234 shares), BlackRock, Inc. (4,282,903 shares), and Siren, L.L.C. (3,240,313 shares).
This table shows the top 171 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.